Načítá se...
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
T cell receptor (TCR)-engineered T cell therapy is a promising cancer treatment approach. Human telomerase reverse transcriptase (hTERT) is overexpressed in the majority of tumors and a potential target for adoptive cell therapy. We isolated a novel hTERT-specific TCR sequence, named Radium-4, from...
Uloženo v:
| Vydáno v: | Mol Ther |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society of Gene & Cell Therapy
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7934585/ https://ncbi.nlm.nih.gov/pubmed/33212301 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2020.11.019 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|